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Abstract: Similarly to other non-spore-forming Gram-positive anaerobes, members of the Actinomyces
genus are important saprophytic constituents of the normal microbiota of humans. Actinomyces
infections are considered to be rare, with cervicofacial infections (also known as ‘lumpy jaw syndrome’)
being the most prevalent type in the clinical practice. Actinomycoses are characterized by a
slowly progressing (indolent) infection, with non-specific symptoms, and additionally, the clinical
presentation of the signs/symptoms can mimic other pathologies, such as solid tumors, active
Mycobacterium tuberculosis infections, nocardiosis, fungal infections, infarctions, and so on. The clinical
diagnosis of actinomycosis may be difficult due to its non-specific symptoms and the fastidious,
slow-growing nature of the pathogens, requiring an anaerobic atmosphere for primary isolation.
Based on 111 references, the aim of this review is to summarize current advances regarding the
clinical features, diagnostics, and therapy of cervicofacial Actinomyces infections and act as a paper
for dentistry specialists, other physicians, and clinical microbiologists.
Keywords: Actinomyces; actinomycosis; cervicofacial infection
1. Introduction, Taxonomy
Actinomyces species (originating from the greek words aktinos (ray) and mykes (fungus),
corresponding to the radial arrangement of the bacterial filaments) are members of anaerobic,
non-spore-forming Gram-positive rods [1,2]. Taxonomically, the genus Actinomyces is part of the
Actinomycetales order of the Actinobacteria phylum (characterized by high guanine-cytosine (G+C)
content in their genome, 55–68% in case of the Actinomyces genus) [3,4]. The Actinomycetales order
includes other clinically important genera, such as Actinobaculum, Actinomadura, Corynebacterium,
Cutibacterium (previously Propionibacterium), Frankia, Gardnerella, Mobiluncus, Nocardia, and Varibaculum.
The genera Actinobaculum, Actinomyces, Mobiluncus, and Varibaculum are the most similar phenotypically,
as they share several characteristics (a highly pleomorphic morphology ranging from branching rods
to coccobacilli, various levels of aerotolerance, and non-acid fast staining, which is an important
differentiating factor from Nocardia species) distinct from the other members of the order [5,6].
Nevertheless, several genera, including Actinomyces, Frankia, Nocardia, and Streptomyces are sometimes
(incorrectly) referred to as the “actinomycetes” group in clinical practice, due to their similar radiating
or branching morphologies (resembling hyphae) and the possession of reproductive asexual spores,
typical for filamentous fungi [7–9]. The genus Actinomyces currently holds 49 species, of which more,
than 26 species have been implicated in human clinical infections (Table 1), however this number may
be a reported estimation only, as these pathogens were frequently misidentified before the introduction
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of current diagnostic technologies (e.g., DNA-DNA hybridization, polymerase chain reaction (PCR),
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), and
next-generation sequencing (NGS)) [1,3,5,7,8,10,11].
Table 1. Actinomyces species implicated in human infections [1,3,5,7,8,10,11].
A. bovis A. graevenitzii A. nasicola A. radingae
A. cardiffiensis A. hominis A. neuii A. timonensis
A. dentalis A. hongkongiensis A. odontolyticus A. turicensis
A. europaeus A. israelii A. oris A. urogenitalis
A. funkei A. massiliensis A. oricola A. viscous
A. georgiae A. meyeri A. pyogenes several novel geno-species
A. gerencseriae A. naeslundii A. radicidentis
Species in boldface represent >90% of species isolated from human infections; A. odontolyticus and A. meyeri are
more frequently implicated in infections of the cervicofacial region, while A. gerencseriae and A. israelii are prevalent
in all types of actinomycoses.
Similarly to other non-spore-forming Gram-positive anaerobes, members of the Actinomyces genus
are important saprophytic constituents of the normal microbiota of animals and humans [2,12,13].
These microorganisms are predominantly found in the human oropharynx, and they are abundantly
present in gingival crevices, periodontal pockets, tonsillar crypts, as well as on carious teeth and in dental
plaques [1,5,8,11,14]. In fact, ~30% of edentulous infants are colonized at the age of 2 months, while at
the age of 12 months, >90% of children harbored these microorganisms in their oral cavities; in these
studies, A. odontolyticus was found to be the predominant member of the genus, while interestingly
A. israelii (the major etiological agent in human infections) was uncommonly isolated [1,5,8,11,14].
Among the results of the National Institutes of Health (NIH) Human Microbiome Project (HMP), other
species, such as A. georgiae, A. gerencseriae, A. israelii, A. meyeri, A. naeslundii, A. odontolyticus, A. oricola,
and A. radicidentis, were also found in the resident flora of the human oral cavity [15]. In addition,
Actinomyces species colonize the upper respiratory tract, gastrointestinal tract and female genital
tract [2,12,13,16]. In contrast, these microorganisms are not normally present on the surface of the skin,
which is dominated by Cutibacterium (previously Propionibacterium) spp. and various staphylococci.
This phenomenon may be due to the secretion of various molecules (fatty acids, antibacterial peptides)
by the above mentioned microorganisms, detrimental to the survival of other species [17,18].
2. Epidemiology, Clinical Presentation
Actinomyces infections in general are considered to be rare (with a reported annual
incidence of 1/300,000 persons), however, the incidence of anaerobic Gram-positive rods may be
underestimated/underreported, as many laboratories still do not have the capabilities or interest
for their full diagnostic workup [5,19]. Additionally, these microorganisms are slow-growing and
have fastidious nutritional requirements, which further discourages some microbiology laboratories
from their precise identification [20]. Actinomyces infections mainly occur among patients between
20 to 60 years of age, while the incidence is greater in males (male-to-female ratio: 3:1) with a
peak between age 40–50 years [2,5,19,21]. Only circumstantial evidence was found why males
are affected more frequently than females, mainly associated with environmental factors, while no
physiological/biochemical/hormonal correlation was described. No racial, seasonal, geographical,
or occupational predilections are associated with the increased occurrence of actinomycoses, however,
before the 1970s, an increased prevalence was noted in rural areas, compared to people living in
urban environments (the observed prevalence was 10:1; cervicofacial and cutaneous actinomycosis:
presumably due to poor hygiene, neglected health status, and low socioeconomic status; pelvic:
in females, due to extended (>5 years) use of intrauterine devices (IUDs) and inadequate knowledge
level on sexual practices), especially in people working with farm animals [5,19]. Anatomically,
Actinomyces infections may be divided to cervicofacial (including central nervous system), abdominal,
thoracic (including lung), pelvic, and cutaneous infections (Table 2), with cervicofacial infections (also
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known as ‘lumpy jaw syndrome’) being the most prevalent type in the clinical practice [1,5,11,19,21–31].
In addition, Actinomyces species were also described in unusual clinical presentations, such as abscesses
of the breasts, groin, perianal, periaural area, and axillae; infections of knee and hip prostheses; and
pericarditis [1,5,11,19,21–31].
Table 2. Clinical manifestations of Actinomyces infections [1,5,11,19,21–31].
Cervicofacial (including Central Nervous System (CNS)) 40–60%
Affected areas:
Upper and lower mandibles 50%
Cheeks 10–15%
Chin 10–15%
Submaxillary ramus and angle, mandibular joints 5–10%
CNS (brain abscess, meningitis, meningoencephalitis, epidural abscess, subdural empyema) 5–10%
Tongue, sinuses, middle ear, larynx, lachrymal pathways, and thyroid gland 0–5%
Abdominal 20–30%
Thoracic (incl. pulmonary) 20–25%
Pelvic 3–5%
Cutaneous 3–5%
Thoracic (and lung) actinomycosis is primarily caused by the aspiration of oral Actinomyces from
saliva (usually presenting with pyogenic infections in the chest wall, ribs and spine), abdominal
infections arise from bowel perforation or increased intestinal permeability (resulting in appendicitis
and colonic or diverticular infections), pelvic actinomycosis is linked to the extensive (i.e., long term) use
of IUDs, while cerebral actinomycosis is primary caused by cervicofacial surgeries or penetrative head
trauma [1,5,11,19,21–29,32]. Adequate and prompt detection of actinomycosis should be performed, as
the associated mortality is between 0 and 28% [19]. Initiation of therapy in cervicofacial infections is also
important for the containment of the infection, as in untreated cases, the pathogens may disseminate
to distant organs—such as the brain, lungs, and gastrointestinal tract—resulting in concomitant
infection [19,21–29]. In fact, hematogenous spread of bacteria from cervicofacial infections are the
second main causes of brain and lung actinomycoses [32–36]. Actinomyces species are frequently
isolated from the bloodstream of patients, following dental extractions (transient bacteremia) or due to
increased permeability of oral mucosa [37,38]. This kind of Actinomyces bacteremia is transient and
should be cleared from the bloodstream in individuals with a healthy immune system [39].
Cervicofacial actinomycosis (as well as Actinomyces infections in other anatomical regions) is
characterized by a slowly progressing (indolent) infection, although in rare cases, a rapid and fulminant
course of infection may also take place (especially in case of immunocompromised patients), which is
caused by infiltration of Actinomyces species (present in the oral cavity) into damaged mucosal
surfaces [11,21]. This mucosal injury may be due to inadequate dental hygiene, various medical
interventions (mainly dental extractions or cervicofacial surgery), or trauma [1,5,11,19,21–29,32].
The general and disease-specific risk factors for developing cervicofacial actinomycosis is presented
in Table 3. While the indolent/chronic form is a relatively painless process at first, patients with
the acute/fulminant form may rapidly experience severe pain [11]. In these infections, chronic,
granulomatous lesions develop, that over time become suppurative in character [5,19]. These lesions
usually form multiple large abscesses (cold abscesses), which are connected by sinus tracts. Sinuses may
express a typical, thick yellow exudate, containing the characteristic sulfur granules of Actinomyces spp.
These granules, which are primarily yellow (but become dark brown later on, due to the deposition of
calcium-phosphate) contain masses of filamentous organisms, bound together by the calcium salts and
biofilm (a protein–polysaccharide complex) [5,19,40]. These granules macroscopically resemble grains
of sand (0.1–1 mm in diameter) and they are important diagnostic markers of Actinomyces species [5,19].
The granulomatous lesions do not respect tissue borders, therefore in advanced stages (due to the
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infiltration of the muscles used in mastication and the jawbone; 10% of cases), severe pain, difficulties
in chewing, trismus may also occur [11]. The affected tissues usually have a hard (some reports say
woody) consistency, due to the corresponding fibrosis and scarring.
Table 3. General and disease-specific risk factors for cervicofacial actinomycosis [1,5,11,19,21–29,41–43].
General Disease-Specific
Human Immunodeficiency Virus (HIV) infection or manifest AIDS Erupting secondary teeth
Hematological malignancies or solid tumors Poor dental hygiene
Organ transplantation (especially in case of the kidneys and lungs) Dental caries
Use of monoclonal antibodies (e.g., anti-tumor necrosis-α-inhibitors,
infliximab, etanercept) Gingivitis
Cancer chemotherapy Mucositis
Corticosteroid use Dental extraction
Malnutrition Introduction of dental implants
Diabetes Cervicofacial surgery
Alcoholism Traumatic injury
Smoking and/or inhalation of particles Bisphosphonate therapy
Low socio-economic status Radiation therapy
Seizure disorders
Crohn’s disease
Hereditary diseases (e.g., hereditary hemorrhagic telangiectasia, chronic
granulomatous disease)
Use of non-steroid anti-inflammatory drugs (NSAIDs)
The disease is often characterized by non-specific febrile episodes, coughs, and sudden weight
loss, while adenopathy is rarely observed. Laboratory findings may include leukocytosis, increased
erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels [41,42]. Of note, the time
period between the onset of the (non-specific) symptoms and the clinical diagnosis may be very long
(6–12 months), which corresponds to erosion and tissue damage in the affected area. The unspecific
nature of the symptoms further delays patients in seeking medical attention [43]. During the formulation
of diagnosis, the clinical presentation, previous medical history of the patient should be considered,
together with the microbiological findings; the growth of Actinomyces species does not definitively
confirm and the absence of the pathogens in culture does not definitively rule out the disease [41–43].
The clinical diagnosis of actinomycosis may be difficult as the clinical presentation of the
signs/symptoms can mimic other pathologies, such as solid tumors, active Mycobacterium tuberculosis
infections, nocardiosis, fungal infections, infarctions (in the lungs), or other granulomatous
diseases [5,21,44–46]. Although Actinomyces species are the primary cause of actinomycoses, there are
usually multiple bacterial species present in these lesions: these pathogens include oral facultative
pathogens, such as Aggregatibacter actinomycetemcomitans, Propionibacterium propionicum, Streptococcus
vidirans group, Gram-positive anaerobic cocci (GPAC), and Gram-negative anaerobic rods [9,47,48].
If the physicians observe suppurative lesions in the submandibular or perimandibular regions, draining
sinus tracts along the jawline and neck, the suspicion of actinomycosis should arise, especially in the
case of relapsing infections [5,21,44–46].
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Actinomyces species have been implicated in two other cervicofacial pathologies, that were
previously considered non-infectious diseases: bisphosphonate osteonecrosis of the jaw and
osteoradionecrosis [5,19,49–52]. In both cases, Actinomyces spp. and biofilm containing sulfur
granules were detected in necrotic bone lesions, presumably further facilitating bone tissue damage.
Radiation therapy is characterized by mucosal disruption and corticosteroid use, while bisphosphonate
therapy in elderly patients is due to osteoporosis; both clinical situations usually correspond to patients
with advanced age and severe underlying conditions, and these medical interventions may additionally
facilitate the invasion of the jawbone by these pathogens (although the exact pathomechanism of these
diseases is still not clear) [5,19,49–52].
3. Pathogenesis of the Infection
There is not much known about the virulence factors of anaerobic non-spore-forming Gram-positive
bacteria [19]. Members of this group (including Actinomyces spp.) are considered to be low-grade
pathogens, without possessing ‘classical’ virulence factors, such as exotoxins [13,14,18,53,54].
Consequently, these microorganisms can only cause disease if the normal mucosal barriers have
been disrupted by exogenous or iatrogenic damage (e.g., surgical intervention, trauma, foreign bodies,
concomitant infections), which explains why the mentioned predisposing factors are necessary for
these infections to occur [14,18,53,54]. As Actinomyces spp. are abundantly present in the normal
flora of humans (especially in the oral microbiome), these infections are mainly endogenous [5,14].
Actinomycoses infections of an exogenous source or interpersonal transmission were not been reported,
apart from so-called “punch or knuckle” actinomycosis, corresponding to punching or biting
injuries [55].
Due to their ability to cause chronic lesions, these microorganisms should have the ability to
evade elimination by the immune system [3,41]. It is hypothesized that the formation of dense,
interlinked chains of branched bacteria in sulfur granules should act as an inhibitor of phagocytic
clearance; however, this phenomenon was not detected in an animal model, where bacteria were quickly
phagocytosed by host defenses [40,56]. As Actinomycosis infections are usually polymicrobial, involving
as many as 5–10 other bacterial species simultaneously, these multispecies (and sometimes multiphyla)
communities are thought to contribute to the pathogenesis of these infections [57]. In polymicrobial
infections, aerobic/facultative anaerobic bacteria enhance the survival of anaerobes by reducing the
oxygen tension in the tissues, by the production of a capsule or toxins, damaging the mucosal barrier,
enhancing the invasiveness of Actinomyces species [18,56]. In addition, the destruction of host tissues is
beneficial for these microbial communities, providing nutrients and Fe2+ ions for all members of the
consortia [40,56]. The presence of foreign bodies (associated with devitalized tissues) further increases
the possibility of invasion [58]. Strong biofilm production has been described in case of A. israelii,
A. naeslundii, and A. viscosus; the biofilm may have a role in the chronic nature of these infections and
their recurrence, and protects against the diffusion of antibiotic molecules [19]. The role of several
other commensal bacteria (e.g., streptococci, Aggregatibacter actinomycetemcomitans, Eikenella corrodens,
Haemophilus aprophilus, and P. propionicum) has been noted in the inhibition of host defenses after a
mucosal breach [9,48].
In addition, the relevance of A. odontolyticus, A. oris, A. naeslundii, and A. viscosus in the formation
of dental plaques was described: these microorganisms are so-called “early colonizers” and they
have the ability to bind statherin and proline-rich proteins in the saliva by their fimbriae, allowing
for their binding onto the surface of teeth [19,33,59–62]. On these surfaces, they may also interact
(co-aggregate) with other members of the dental plaque microorganisms (e.g., Fusobacterium, Prevotella,
and Veillonella species). In the presence of fermentable carbohydrates, Actinomyces species also produce
acid, leading to dental caries and tooth decay. The significance of these fimbriae is also pronounced in
osteomyelitis, where they bind collagen and contribute to the pathogenesis of bone necrosis [63–66].
It has been described that A. meyeri has a great propensity for hematogenous dissemination; however,
no differentiating virulence factor has been identified [22,35]. Similarly, several species (A. naeslundii,
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A. odontolyticus, A. gerencseriae, A. neuii, A. turicensis, and A. radingae) have been implicated in
anatomically specific clinical syndromes, which may be mediated by some form of tissue tropism or
specific virulence determinant [19,33,59–62].
4. Isolation and Identification of Actinomyces spp. from Clinical Specimen
Isolation and identification of Actinomyces spp. is a very important step in the diagnostic procedure
of this disease and laboratory confirmation of these infections is often difficult [5]. The gold standard
for the diagnosis of cervicofacial actinomycosis is culture, histological examination of a tissue sample,
pus or abscess. Similarly to other anaerobic pathogens, the best clinical specimens for isolation are
tissue biopsy samples, deep needle aspirates, joint fluids, pus, root canal exudates, aseptically collected
peripheral blood and subgingival plaque (or bone, if osteomyelitis is suspected); while cutaneous
or mucosal swabs, sputum, bronchial washing liquid (except for MiniBAL) and urine (except for
suprapubic bladder aspirates) are not suitable for identification [10]. In addition, Actinomyces needs
to be isolated from anatomical areas possessing rich commensal microbiota, therefore special care
needs to be taken during sample collection (Figure 1) [67]. Depending on the infection site, Actinomyces
may be co-isolated with normal commensals, such as members of the Enterobacteriaceae, Staphylococcus
spp., Streptococcus spp., and E. corrodens among facultative anaerobes; and A. actinomycetemcomitans,
Bacteroides spp., Capnocytophaga spp., Prevotella spp., and Veilonella spp. among anaerobes [18,67,68].
For this reason, isolation of Actinomyces from a sterile body site (or the isolation of a limited number
of microorganisms) usually has clinical significance, while from other sample types, the isolation of
these microorganisms can be considered as contamination (or their significance should be evaluated by
the treating physician). If polymicrobial infections is suspected, obtaining pure cultures of all of the
relevant organisms present should be attempted. Additionally, recent broad-spectrum antibiotics may
also reduce microbial diversity, which may also be misleading [5,10].
The use of anaerobic transport techniques and pre-reduced anaerobically sterilized (PRAS) media
is essential for successful recovery of these microorganisms [18]. Although these pathogens are more
tolerant to atmospheric oxygen than most anaerobic bacteria, Actinomyces often fail to grow aerobically;
therefore, the culture plates should be incubated in strict anaerobic condition (especially for their primary
isolation [5,69]. This may be performed using anaerobic jars or boxes, with the help of GasPak™ sachets
(convenient for smaller laboratories, but these should not be prematurely opened as this could result in
an oxygen shock for anaerobic microorganisms) or anaerobic glove boxes (ideal for reference laboratories
with large volume of samples, allows for manipulation and examination of samples in anaerobic
atmosphere, expensive) [10,18,70]. Both enriched culture broth (brain–heart infusion) and non-selective
and selective solid media (arginine–glycerine agar) should be used for the successful isolation of
Actinomyces spp.; metronidazole may act a selective agent for most other anaerobes, while nalidixic
acid should be used to eliminate facultative anaerobic Gram-negative bacteria [67,71]. Actinomyces spp.
are fastidious, slow-growing microorganisms, bacterial colonies may appear after 3–7 days; however,
this may take up to 14 days, therefore extended incubation times should be applied before the final
microbiological report is released [72]. The communication between the clinician and microbiologist
is imperative in these cases, as the physicians should notify the laboratory about the suspicion of
cervicofacial actinomycosis [43]. In case of bone involvement, even longer incubation is recommended,
due to the reduced growth properties of bacteria in this niche [43]. Although it is important to note that
in around ~50% of cases, culture results are negative, especially if the samples were taken after the onset
of antimicrobial therapy (which is frequent following dental procedures or cervicofacial surgery) [20].
Presumptive identification of these microorganisms is based on their morphology (clumping in liquid
culture, white colonies with a domed surface or molar tooth-shaped morphology on solid media, which
may become irregular after an extended incubation time), Gram-stain morphology, acid-fast negativity,
indole-negativity, and metronidazole-resistance [8,67,73]. Additional (species-level) identification may
be performed in tertiary-care centers or anaerobic reference laboratories, using biochemical testing
methods (e.g., in-house biochemical panels, API 20A, VITEK 2 ANC card), gas-liquid chromatography,
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molecular methods (DNA–DNA hybridization, PCR, 16S rRNA gene sequencing, and fluorescence in
situ hybridization), and MALDI-TOF MS [51,74–78]. Serology is of no relevance in the diagnosis of
actinomycosis [5,21,41].
The use of MALDI-TOF MS for diagnostic purposes has revolutionized routine clinical
microbiology, and this is especially true for the identification of anaerobic bacteria [79–82]. MALDI-TOF
MS has allowed for the correct and precise identification of anaerobes in a clinically-relevant time frame,
right after the appearance of the bacterial colonies on agar media, reducing the turnaround time for
the processing of individual samples (compared to conventional, biochemical-based methods) [83,84].
Currently, two major MALDI-TOF MS systems are available: the Microflex MALDI-TOF MS (Bruker
Daltonik GmbH, Bremen, Germany) and the VITEK MS MALDI-TOF (bioMérieux) [85,86]. Both of
these instruments utilize a database of existing reference spectra (Biotyper for Bruker (Bruker Daltonik
GmbH, Bremen, Germany) and Saramis for bioMérieux (bioMérieux, Marcy-l’Étoile, France)) [85].
Several studies have reported on the identification efficacy of Actinomyces using direct inoculation onto
the MALDI-TOF stainless steel plate; however, on-plate extraction with 70% ethanol or formic acid or
a complete extraction before the MALDI-TOF measurements has increased the rate of species-level
identification for Gram-positive anaerobes [87]. However, there are currently no studies detailing on
the clinical impact (i.e., benefit) of species-level identification of Actinomyces species, as the therapeutic
approach for these infections is very similar, irrespective of the species of the pathogen [88,89].
The macroscopic and direct microscopic examination of pus collected from the suspected lesions is
of critical importance in the diagnosis of actinomycosis [5]. As the colony counts of these microorganisms
is usually low in pus, a large volume of sample or several samples should be collected and examined.
Sulfur granules are suggestive of the presence of Actinomyces spp., while contamination may be
suspected in the absence of these granules and a typical clinical syndrome, however, it is not specific
enough for definitive diagnosis (they are absent in ~50% of samples, and similar granules may be
observed in N. asteroides/brasiliensis and Streptomyces madurae infections) [19]. If possible, these sulfur
granules from the sinuses or tissue biopsy should be crushed and examined microscopically after
Gram-staining (or methylene blue), where Gram-positive, thin rods should be observed with a branching
morphology. These bacterial cells may also be surrounded by inflammatory (polymorphonuclear
leukocytes, PMN) cells, plasma cells and fibroblasts [1]. Histological examination of tissue samples is
also an important cornerstone of diagnosis. Various staining methods, such as periodic acid-Schiff
staining, hematoxylin-eosin, Gömöri’s methenamine silver stain, and fluorescein-conjugated specific
antibodies may be used for this purpose [1]. Histological examination detects the characteristic granules
and bacterial mycelia in ~75% of cases [19]. Cytology is the most sensitive method for the detection of
Actinomyces spp. in suspected pelvic actinomycosis [26]. Although they may not be contributory to
the establishment of positive diagnosis, imaging technologies may be useful in the differentiation of
suppurative lesions caused by Actinomyces from malignancy [29,44–46,73,90–93]. Dental panoramic
radiographs, computer tomography (CT), and magnetic resonance imaging (MRI) are also valuable
in the evaluation of the extent of tissue involvement (whether bone tissue is involved) and size and
location of the granulomatous lesion [29,44–46,73,90–93] (Figure 1).
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Figure 1. Schematic diagnostic algorithm for the clinical diagnosis of Actinomyces infections (for detailed
explanation, see Sections 2–4).
5. Therapy of Actinomycoses
When considering the antimicrobial therapy of Actinomyces infections, clinicians should be
aware of the antibiotics having anti-anaerobe activity [94]. The complete list of these antibiotics,
the rationale behind their clinical efficacy and global resistance levels are beyond the scope of
this review, for further reading, see another publication by the authors [18]. Anaerobes with a
high oxygen tolerance due to the presence of various enzymes (i.e., Actinobaculum, Actinomyces,
Bifidobacterium, Lactobacillus, Propionibacterium) or strictly anaerobic genera (e.g., Atopobium, Eggerthella,
Eubacterium, and Mobiluncus) due to other mechanisms are intrinsically resistant to metronidazole,
which is considered to be the therapy-of-choice for other anaerobic genera (e.g., B. fragilis, Clostridium
species) [95,96]. Aminoglycosides have no activity against anaerobes in general (including Actinomyces),
while fluoroquinolones (ciprofloxacin, levofloxacin, and moxifloxacin), sulfamethoxazole/trimethoprim
are usually considered to be inactive [97,98]. Amongβ-lactam antibiotics, penicillinase-stable penicillins
(such as oxacillin and cloxacillin), first generation cephalosporins (cephalexin) and aztreonam are also
ineffective. Doxycycline could be considered as a viable therapeutic option (and there are several
reports of clinical success with this drug); however, resistance levels in anaerobes globally are very
high, discouraging the use of this agent in first-line therapy [18,32,99].
The first-line therapy of actinomycosis is high-dose therapy with intravenous penicillin G
(12–24 million U/day for adults) or ampicillin for 2–6 weeks, which should be replaced in a
sequential fashion (and if clinical improvement is observed) by penicillin V or amoxicillin per os
for an extended period of time (6–12 months) to prevent relapse [1,5,19,100]. If it is clinically reasonable,
intravenous agents may include more broad-spectrum agents, such as piperacillin-tazobactam, cefoxitin,
ceftriaxone, and carbapenems. In the case of penicillin-hypersensitivity, other drugs should be
considered: clindamycin (good penetration into abscesses), macrolides (erythromycin, clarithromycin,
or azithromycin), doxycycline, tigecycline, and chloramphenicol [27,101–103]. In actinomycoses,
the elimination of Actinomyces spp. is generally considered to be adequate for clinical cure, however in
severe cases or for immunosuppressed patients, antibiotic therapy should target all isolated species [11].
If polymicrobial infection is suspected, a β-lactam/β-lactamase-inhibitor combination, carbapenems,
aminoglycosides (e.g., for Enterobacteriaceae), or metronidazole (against other anaerobes) should
also be administered in the therapeutic regimen [41]. However, the dogma of prolonged therapy
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in actinomycoses has been challenged by several reports, where shorter (1–4 week) therapeutic
regimens were also reported to be successful [104–106] (Table 4). Especially in mild cases (i.e., no bone
involvement) of cervicofacial and thoracic actinomycoses, satisfactory cure rates have been observed
with short-term oral-only antibiotic therapy, coupled with proper surgical debridement, without
relapses. Nevertheless, more clinical studies are required to warrant a change in current therapeutic
guidelines, as this topic is still very controversial [104–106].
Resistance levels of anaerobic bacteria are generally considered to be predictable, and because
of this, routine antimicrobial susceptibility testing is not indicated in Actinomyces spp., only for
reference laboratories for surveillance purposes [107,108]. The gold standard method for antimicrobial
susceptibility testing of anaerobes is the agar dilution method (recommended by the Clinical and
Laboratory Standards Institute; CLSI), which is a very expensive and labor-intensive technique,
recommended for anaerobic reference centers [109,110]. Drug resistance (excluding intrinsic resistance
mechanisms) is not a relevant issue in Actinomyces species, as their susceptibility levels to penicillin,
amoxicillin, piperacillin-tazobactam, ceftriaxone, and carbapenems is near 100%, although the use of
broad-spectrum agents is discouraged if additional etiologies are not considered [48,107,108]. However,
some minor differences between Actinomyces species have been observed: while these microorganisms
do not produceβ-lactamases, blaTEM-typeβ-lactamases were detected in A. graevenitzii and A. europaeus,
conferring resistance to ceftriaxone and piperacillin-tazobactam [107,111]. Additionally, there have
been reports of Actinomyces spp. with high minimum inhibitory concentrations for tetracycline and
meropenem [19]. Despite prolonged therapy with large doses of antibiotics, recurrence actinomycoses is
common; however, this problem is more pertaining to pharmacokinetics (i.e., poor tissue penetration of
antibiotics in the inflamed tissue, inadequate blood supply, and production of biofilm), and presumably
not related to drug resistance [107,108].
Table 4. Therapeutic considerations for Actinomyces infections.
Antibiotic Therapy
Should be Considered Should NOT be Considered
Penicillin G Metronidazole *
Penicillin V Aminoglycosides *
Ampicillin Other β-lactam-β-lactamase-inhibitor combinations *
Amoxicillin Penicillinase-stable penicillins
Piperacillin/tazobactam First generation cephalosporins (cephalexin)
Second generation cephalosporins with
anti-anaerobic activity (cefoxitin) Aztreonam *
Third generation cephalosporins (ceftriaxone) Sulfamethoxazole/trimethoprim *
Carbapenems Fluoroquinolones *
Doxycycline
Tigecycline
Clindamycin
Macrolides
Chloramphenicol
Adjunctive Therapy
Surgical debridement, drainage
Photodynamic therapy
Laser therapy
* Should be reconsidered in case of polymicrobial infections (e.g., Enterobacteriaceae, other anaerobes).
Although antibiotic therapy is the basis of Actinomyces infections, surgical interventions should also
be considered [1,5,19]. In mild cases, surgery may have an adjunctive role in therapy (as debridement
reduces the formation of scar tissue) and may reduce the duration and dose of antibiotic treatment
required. However, in severe cases, drainage of the formed abscesses to relieve obstruction, excision
of sinus tracts, fistulas, and necrotic tissues is required for clinical success. Imaging techniques may
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be used to monitor response to treatment [1,5,19,92]. Additionally, the presence of any malignancy
can be also ruled out during surgical intervention. There are several reports on the therapeutic use of
photodynamic therapy and laser therapy; however, the relevance of these techniques in clinical practice
should be further evaluated [1,5,19,100]. For the prevention of cervicofacial actinomycoses, good oral
hygiene practices, regular dental checkups (especially for patients with dental prostheses), and specific
lifestyle choices (pharmacological control of diabetes, cessation of smoking, reduced alcohol intake)
are recommended.
6. Conclusions
Due to its relatively rare occurrence, human Actinomyces infections are considered to be a
neglected disease (the WHO does not maintain a current statistical database on the global prevalence
of actinomycoses); however, due to an increase in the number of immunocompromised patients and
the wider availability of dental procedures worldwide, the prevalence of this illness is thought to be
increasing. Especially in the case of cervicofacial actinomycosis (the most prevalent form of the disease),
clinicians—from primary care physicians to surgeons—dentists and clinical microbiologists should
familiarize themselves with this condition to allow for its prevention (in the presence of relevant risk
factors) appropriate diagnosis and therapy. The distinction between actinomycosis and other infectious
(tuberculosis, nocardiosis, fungal infections) and non-infectious (tumors) pathologies should be the
first diagnostic step, and all relevant diagnostic modalities should be utilized. Because culture results
and the presence of the characteristic sulfur granules is not specific enough for definitive diagnosis,
the underlying conditions and present symptoms of the patient should be consulted. Patients usually
present with extensive tissue damage and severe symptoms, due to the slow progression and indolent
nature of the disease. On a positive note, the response to the adequately long antimicrobial therapy
is usually good, even in patients where extensive necrosis and tissue damage has already occurred.
Continuous education of healthcare professionals and a high degree of suspicion is imperative for the
apt management of Actinomycosis infections.
7. Literature Search
To formulate the present manuscript, a literature search was performed by the authors in the
PubMed/MEDLINE, EMBASE, and Web of Science databases up to 30th of May, 2019, using the
following search keys: “Actinomyces OR actinomycosis OR actinomycoses OR lumpy jaw syndrome OR
A. gerencseriae OR A. israelii OR A. meyeri OR A. odontolyticus”. There were no restrictions on article type
or language. Two independent authors (M.G. and G.T.) examined the search results and selected papers
based on the suitability to be included in this review paper. After the selection of appropriate articles,
the reference list of these papers was also screened for relevant papers in the topic. Additionally, in case
of several sub-topics of the review (e.g., MALDI-TOF for the diagnostics of anaerobes), authors also
used references from their personal collection, totaling in n = 111 references.
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AIDS acquired immunodeficiency syndrome
CNS central nervous system
CRP C-reactive protein
CT computer tomography
DNA deoxyribonucleic acid
ESR erythrocyte sedimentation rate
G+C guanine-cytosine content
GPAC Gram-positive anaerobic cocci
HIV human immunodeficiency virus
HMP Human Microbiome Project
IUD intrauterine device
MALDI-TOF MS matrix-assisted laser desorption/ionization time-of flight mass spectrometry
MRI magnetic resonance imaging
NSAID non-steroidal anti-inflammatory drugs
NGS next-generation sequencing
NIH National Institutes of Health
PCR polymerase chain reaction
PMN polymorphonuclear neutrophils
PRAS pre-reduced anaerobically sterilized
WHO World Health Organization
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